^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    domatinostat (4SC-202)

    i
    Company:
    4SC
    Drug class:
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, LSD1 inhibitor
    Related drugs:
    Apply
    Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI) (NCT04133948)
    Phase 1/2
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    11/15/2023
    Initiation :
    01/07/2020
    Primary completion :
    01/11/2022
    Completion :
    11/01/2024
    IFNG
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
    Pre-operative Immunotherapy in Stage II-III Urothelial Cancer (TURANDOT) (NCT04871594)
    Phase 1b
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    10/09/2023
    Initiation :
    08/23/2021
    Primary completion :
    06/02/2023
    Completion :
    06/02/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
    Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (NCT03812796)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Unknown status
    Last update posted :
    02/05/2019
    Initiation :
    01/11/2019
    Primary completion :
    11/30/2021
    Completion :
    11/30/2021
    MSI
    |
    Bavencio (avelumab) • domatinostat (4SC-202)